Vaginosis, BacterialPhase 2/3GYNBAL-RBVNCT07527572
Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis
A Phase 2/3 study testing Lactobacillus gasseri KABP®064 10e9 CFU/capsule in people with Vaginosis, Bacterial and Bacterial Vaginosis, run by Kaneka Americas Holding Inc..
Trial summary
The vagina is a dynamic muscular organ whose health relies on a Lactobacillus-dominant microbiota that maintains low pH and protects against infections. Bacterial vaginosis (BV) is the most common vaginal imbalance in women of reproductive age, caused by depletion of protective Lactobacillus species and overgrowth of… Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Vaginosis, Bacterial, Bacterial Vaginosis, Bacterial Vaginosis (BV)
- What is being tested?
- Lactobacillus gasseri KABP®064 10e9 CFU/capsule
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 160 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2026to 1 Oct 2027
- Phase
- Phase 2/3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Females of ages 18-45 years (both values included) who are premenopausal.
- History of recurrent BV (at least 3 episodes in the last 12 months with at least one of them documented in the last 6 months).
- Positive Amsel's criteria (confirming active BV) determined by at least 3 out of the following 4 symptoms or signs:
- Homogeneous, thin, yellowish-white/greyish white discharge that smoothly coats the vaginal walls.
- Presence of the clue cells on microscopic examination (as assessed by wet mount test).
- A fishy odor of vaginal discharge after adding 10% potassium hydroxide (KOH) solution to wet mount - also known as "whiff test".
Show all 13Show fewer
- Vaginal pH > 4.5
- Imbalance in vaginal pH (pH > 4.5).
- Participants with Body Mass Index (BMI) 18.5-32.0 kg/m2.
- Non-smokers.
- Participants able to comply with and perform the procedures requested by the protocol (including dietary restrictions, consumption of study treatments, blood and urine sample collection procedures and study visit schedule).
- Participants who are literate enough to understand the essence of study, are informed about the purpose of the study, and understand their rights.
- Participants able to give written informed consent and willingness to participate in the study and comply with its procedures.
Who cannot join
- Participants currently taking contraceptives and/or sexual hormones.
- Pregnant or breastfeeding.
- Menstrual period expected within the next 6 days of screening.
- Irregular cycle ("irregular" (e.g., less than 21 or more than 35 days consistently, or cycle variability more than 4 days month-to-month).
- Participants who have documented resistance to metronidazole.
- Participants diagnosed with any vaginal or urinary tract infection other than BV.
Show all 21Show fewer
- Participants who have used other probiotics or antibiotics (vaginal, oral, parenteral) in the last 15 days.
- Participants using other vaginal products with bacteriostatic or bactericide activity (such as lactic acid gels, herbal extracts, dequalinum chloride, etc.).
- Participants with an intrauterine contraceptive device (IUCD/IUD) in situ at screening.
- Participants who have undergone total hysterectomy or any other surgery involving the female reproductive system.
- Women diagnosed with Sexually transmitted infections (STIs) or Human immunodeficiency virus (HIV) infection.
- Participants diagnosed with Polycystic ovary syndrome (PCOS) or other such diseases that further affect the hormonal homeostasis in women.
- Presence of uncontrolled diabetes mellitus (Indicated by Fasting Blood Glucose (FBG) more than or equal to 126 mg/dL. Fasting is defined as no caloric intake for at least 8 hours).
- Presence of uncontrolled hypertension (Defined as Systolic Blood Pressure (SBP) more than or equal to 140 mm Hg and/or Diastolic Blood Pressure (DBP) more than or equal to 90 mm Hg).
- Untreated previously diagnosed thyroid disorders.
- Participants who have a history of any significant neurological and psychiatric condition which may affect the participation and inference of the study's end points.
- Participation in other clinical trials in last 3 months prior to screening.
- Participants with substance abuse problems defined as:
- High-risk drinking as defined by consumption of 4 or more alcohol containing beverages on any Day or 8 or more alcohol containing beverages per week for women.
- Participants who have any of the following clinically significant illness, i.e., Cardiovascular, endocrine system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, neuropsychiatric, musculoskeletal, inflammatory, blood and tumors, chronic gastrointestinal diseases, etc.
- Any condition that could, in the opinion of the Investigator, preclude the participant's ability to successfully and safely complete the study or that may confound study outcomes.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis.
The vagina is a dynamic muscular organ whose health relies on a Lactobacillus-dominant microbiota that maintains low pH and protects against infections. Bacterial vaginosis (BV) is the most common vaginal imbalance in women of reproductive age, caused by depletion of protective Lactobacillus species and overgrowth of anaerobic bacteria such as Gardnerella vaginalis. BV affects an estimated 23-29 percentage of women globally (10-30 percentage in India) and is associated with discharge, odor, discomfort, and significant risks including recurrent disease, adverse reproductive outcomes, and increased susceptibility to STIs. Although antibiotics are effective for acute treatment, recurrence rates are high (50-60 percentage within 12 months), highlighting an unmet need for preventive strategies.
Probiotics, particularly Lactobacillus species, have emerged as promising options to restore vaginal microbiota balance and reduce BV recurrence. Lactobacillus gasseri is a natural vaginal commensal with antimicrobial activity against BV pathogens and the ability to lower vaginal pH. L. gasseri KABP®064 has demonstrated vaginal colonization after oral administration, good tolerability, and potential to promote vaginal health.
The present randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of oral L. gasseri KABP®064 in preventing BV recurrence over six months following standard antibiotic therapy. Outcomes include recurrence rates and timing, symptom severity, microbiological balance, inflammation markers, and patient-reported vaginal health, supporting a microbiome-focused, non-antibiotic approach to BV recurrence prevention.
- Being tested
- Lactobacillus gasseri KABP®064 10e9 CFU/capsule, Placebo (maltodextrin)
- Keywords
- Recurrence, Microbiome, Metronidazole, Bacterial Vaginosis
- Medical subject headings
- Vaginosis, Bacterial, Recurrence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lactobacillus gasseri KABP®064 10e9 CFU/capsuleDietary supplement
Phase 1: 15 days, 1 capsule/day post-randomization. Phase 2: 10 days per month for ~6 months, starting 6th day of menstruation, 1 capsule/day.
Placebo (maltodextrin)Dietary supplement
Phase 1: 15 days, 1 capsule/day post-randomization. Phase 2: 10 days per month for ~6 months, starting 6th day of menstruation, 1 capsule/day.
| Study group | Role | What they receive |
|---|---|---|
| Probiotic | Experimental | Lactobacillus gasseri KABP064 in delayed-released (DR)-capsules. Strength: 1 x 10^9 CFU/capsule Receives: Dietary Supplement: Lactobacillus gasseri KABP®064 10e9 CFU/capsule |
| Placebo | Placebo comparator | Placebo capsules filled with maltodextrine. Exact same appearance as active capsules. Receives: Dietary Supplement: Placebo (maltodextrin) |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the efficacy of Lactobacillus gasseri KABP®064 in preventing recurrence of BV infections, diagnosed using Amsel criteria, over a period of 6 months as compared to placebo.
Amsel criteria (≥3 out of 4 positive)
Measured: Day 6 to Day 180
Secondary outcomes (15)
Analysis of BV recurrences diagnosed using Nugent score (≥ 7) (main secondary endpoint)
Compared to Placebo
Measured: Day 6 to Day 180
Analysis of BV recurrences diagnosed using both Amsel criteria (≥ 3 of 4 positive) and Nugent score (≥7)
Compared to placebo
Measured: Day 6 to Day 180
Time to first BV recurrence as per Amsel's criteria (≥3 of 4 positive) and/or Nugent Score (≥7)
Compared to Placebo
Measured: Day 6 to Day 180
Proportion of participants experiencing 2 or more, and 3 or more BV infections during the study period.
Compared to Placebo
Measured: Day 6 to Day 180
Percentage of patients receiving first-line or second-line SOC and duration (days).
Compared to Placebo
Measured: Day 6 to Day 180
Absolute difference in the duration of the SOC consumption (days).
Compared to Placebo
Measured: Day 6 to Day 180
Reducing the duration and severity of symptoms (itching, vaginal discharge, and odor) assessed by Visual Analogue Scale (VAS).
Compared to Placebo
Measured: Day 0, Day 6, Day 22, Day 90, Day 180, and at recurrence visits (if patients have a BV recurrence during the study time frame, they will ask for a "recurrence visit" to assess medication and some study parameters).
Percentage of patients with recovery of normal Nugent score (0-3).
Compared to Placebo
Measured: Day 6 to Day 22
Vaginal health by International Consultation on Incontinence Questionnaire - Vaginal symptoms (ICIQ-VS).
Compared to Placebo
Measured: Day 0, Day 6, Day 22, Day 90 and Day 180
Change in vaginal pH assessed by vaginal pH strip method.
Compared to Placebo
Measured: Day 0, Day 6, Day 22, Day 90, Day 180, and at recurrence visits (if patients have a BV recurrence during the study time frame, they will ask for a "recurrence visit" to assess medication and some study parameters).
Concentration of proinflammatory cytokines.
Compared to Placebo
Measured: Day 0, Day 22
Relative abundances of lactobacilli and common pathogens associated to BV assessed by using Next-Generation Sequencing (NGS).
Compared to Placebo
Measured: Day 0, Day 6, Day 22, Day 90, Day 180
Percentage of women with vaginal Community State Types (CSTs) associated to healthy vaginal microbiota.
Compared to Placebo
Measured: Day 0, Day 6, Day 22, Day 90, Day 180
Analysis of BV recurrences (including intermediate BV) as confirmed per Amsel criteria (≥ 3 of 4 positive) and Nugent score (score≥4) throughout the 6-month period.
Compared to Placebo
Measured: Day 6 to Day 180
Analysis of BV recurrences (including intermediate BV) as confirmed per Nugent score (score ≥4) throughout the 6-month period.
Compared to Placebo
Measured: Day 6 to Day 180
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2026
- Study start1 Apr 2026 (estimated)
- Primary completion1 Apr 2027 (estimated)
- Study completion1 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vaginosis, BacterialStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kaneka Americas Holding Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Vedic Lifesciences Pvt. Ltd., AB-Biotics
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07527572
- Sponsor's protocol ID
- 241002/IP/BV
- Acronym
- GYNBAL-RBV
- Status last verified
- Apr 2026
- First submitted
- 25 Mar 2026
- Last updated
- 14 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No